Theratechnologies Inc. (NASDAQ: THTX) – Q1 2025 Earnings
Theratechnologies Inc. (NASDAQ: THTX) – Q1 2025 Earnings
Earnings Release Date: Apr. 9, 2025
Stock Price: $1.55
Market Cap: $76.5 million
Q1 2025 sales of $19.05 million vs $16.25 million in the prior year
Q1 2025 EPS of $0.00 vs ($0.10) in the prior year
Press Release vs Call Transcript Comparison
Seasonality & One-Time Events: Both documents clarify that Q1 outperformance is not all organic; Q2 is likely to look flat or down, which could surprise models not accounting for channel inventory quirks.
Cash Flow and Liquidity: Management explicitly links continuing as a going concern to the success of the EGRIFTA WR transition and cash generation; covenant compliance is flagged as critical.
Focus on Execution: Calls emphasize operational priorities (transition planning, supply chain risk mitigation, internal expense control—e.g., selling and R&D expenses stabilizing or decreasing).
Trogarzo’s Potential Rebound: Press release suggests decline is ongoing; call offers a more nuanced, possibly more optimistic view.
Guidance Provided/Confirmed: Both documents reaffirm full-year 2025 guidance ($80–83M revenue; $10–12M adj. EBITDA), but the call provides color on risks and assumptions underlying these numbers.
Positive Insights
Negative Insights
Tariff Risk
Tariffs and trade risks were actively monitored by management. The company currently manufactures EGRIFTA SV in both the U.S. and Canada and acknowledged that, while some supply chain exposure remains, anticipated U.S. tariff impacts are marginal. Mitigation is in progress—manufacturing for the F8 formulation will soon transition entirely to the U.S., essentially removing cross-border supply risk. Management stated there is no expected tariff impact on Trogarzo or the Ionis products, as these products either involve transfer pricing or are manufactured outside the U.S./Canada corridor. Forward-looking, tariff risk will decline as operational changes take effect, supporting margin stability and continuity of supply.
Previous Earnings Call
Quarter-over-quarter comparison
Theratechnologies exited 2024 with momentum, celebrating a strategic repositioning, new partnerships (Ionis), and top-tier EBITDA performance—confidently telling investors that the company had turned a corner and was positioned to aggressively scale. The focus was on expansion, new high-value assets, and maximizing the EGRIFTA franchise’s differentiation.By early 2025, the narrative pivoted: leadership confronted the operational realities of a drug shortage, prioritized restoring patient access, and stabilized finances despite temporary turbulence. The Q1 2025 call’s tone is more conservative and execution-oriented—championing the company’s ability to rebound, restore growth in enrollments, and manage through a prickly formulation transition. While still bullish on medium-term drivers, management’s immediate energies are squarely on effective execution, cash discipline, and ensuring a seamless EGRIFTA WR rollout, all with a watchful eye on risk—be it tariffs, inventory cycles, or competitive churn.
Year-over-year comparison
In Q1 2024, Theratechnologies told a story of a company emerging from a period of volatility, focusing on cost discipline, regaining commercial traction, and nurturing pipeline innovation—all while candidly addressing “noisy” inventory and revenue timing issues. Management was optimistic, but acknowledged the need for stable, repeatable execution before expanding ambitions.
By Q1 2025, the narrative matures: the company has weathered a real-world disruption (EGRIFTA SV supply interruption), responded with operational agility, and is now laser-focused on disciplined execution of the F8/WR transition and on fortifying its profitability in the face of ongoing competitive and supply chain risks. Risk management, transparency, and an emphasis on sustainable, repeatable performance now define the tone. No longer just promising “EBITDA positivity,” management is openly managing quarterly volatility and planning for the future with both optimism and healthy caution.
Final Takeaway
Theratechnologies is in a transitional growth phase, leveraging the launch of EGRIFTA WR to drive the next leg of franchise expansion while recovering from a one-off supply disruption. Execution on the transition to the new formulation and conversion of adjusted EBITDA into sustained cash flow are key. While growth indicators and catalysts are in place, near-term financial results will be pressured by inventory headwinds, and underlying cash generation requires close monitoring. Verdict: Hold, with potential for upside if transition risk is well managed, but downside if cash conversion or operational execution falter.